BDAL, which got a DoD order for ion trap MSs recently, now teams up with its sister companies for another deal:
>>SAN DIEGO, Oct 3, 2001 (BW HealthWire) -- GeneFormatics Incorporated, an innovator in the field of structural proteomics, and Bruker AXS Inc., Bruker BioSpin Corporation and Bruker Daltonics Inc. (NASDAQ: BDAL chart, msgs) today announced that they have formed strategic partnerships that encompass the development of next-generation technologies for the experimental analysis of three-dimensional protein structures, the supply of various research infrastructure systems, as well as equity investments. GeneFormatics uses its high-throughput "function first" approach to assign protein function to accelerate the discovery of new medicines and other useful products. These in silico-derived discoveries allow its scientists to accurately and rapidly determine which proteins are the best prospects for further analysis by experimental 3-D structure elucidation technologies.
Under the agreements, GeneFormatics and the three Bruker companies will collaborate in the development of three experimental technologies deployed by GeneFormatics in its fully integrated DIAMOND(TM) structural proteomics platform, including high-throughput NMR(1) spectroscopy (Bruker BioSpin), X-ray SCD(2) (Bruker AXS), and MALDI-TOF(3) mass spectrometry (Bruker Daltonics). Additionally, the three Bruker companies will make undisclosed equity investments in GeneFormatics' Series C round, and GeneFormatics will make undisclosed equity cross-investments in Bruker AXS and Bruker Daltonics.
"With these agreements, GeneFormatics will further enhance its already state-of-the-art 3-D structure analysis technologies by collaborating with a group of the leading life science systems manufacturers in the world," said John Chiplin, Ph.D., President and CEO of GeneFormatics. "Bruker BioSpin's world class NMR technologies truly complement the AutoAssign and AutoStructure technology developed by Dr. Gaetano Montelione, which GeneFormatics has exclusively licensed from Rutgers University."
"GeneFormatics' approach breaks through the structural proteomics bottleneck by using 3-D analysis technologies, such as ours, only on those proteins of greatest medical or chemical interest," said Frank H. Laukien, Ph.D., President and CEO of Bruker Daltonics and Chairman of Bruker AXS. "We see high value in what GeneFormatics' scientists and consultants will provide to us in advancing our technologies. Our investment in GeneFormatics is a sound business strategy to support a leading player in the structural proteomics marketplace."
As part of the agreements, the companies intend to jointly develop improved methods for high-throughput analysis of protein structures by various methods. GeneFormatics will also gain access to and become a test site for new biological mass spectrometry, X-ray SCD, and NMR spectroscopy related technologies developed by the Bruker companies as they become available.
About GeneFormatics
GeneFormatics Incorporated, an innovator in the field of structural proteomics, integrates proprietary computational and experimental technologies to rapidly discover novel protein function and structure information on an unprecedented scale. This information accelerates drug discovery and product development by enabling more efficient target prioritization leading to pharmaceuticals and agrochemicals. GeneFormatics has generated novel information about proteins in key microbial and model proteomes, and is currently employing its technology platform to obtain valuable proprietary information for thousands of potential drug targets in the human proteome.
About the Bruker companies
Bruker AXS Inc. is a leading developer and provider of a diverse set of life science and advanced materials research tools based on X-ray SCD technology. The company develops, manufactures, and markets worldwide advanced X-ray solutions for the three-dimensional structure determination of biological and chemical compounds, as well as for advanced materials research and analysis. Its diverse customer base includes pharmaceutical and biotechnology companies, advanced materials, semiconductor, synthetic polymer, and basic materials companies, as well as university and government research customers. Applications include X-ray crystallography for structural proteomics, and automated systems for combinatorial materials science.
Bruker BioSpin Corporation designs, manufactures, and distributes enabling life science tools based on core magnetic resonance technology. Bruker BioSpin's technology platforms include NMR, EPR, MRI, as well as superconducting magnets. Bruker BioSpin is a market and innovation leader in NMR, with design, manufacturing, and applications centers in Europe, North America, and Japan, as well as applications and customer support facilities in most industrialized and developing countries.
Bruker Daltonics Inc. is a leading developer and provider of innovative life science systems based on mass spectrometry. Its substantial investment in research and development allows it to design, manufacture and market a broad array of products intended to meet the rapidly growing needs of a diverse customer base, including pharmaceutical companies, biotechnology companies, proteomics companies, molecular diagnostics companies, academic institutions and government agencies. For further information, check: www.bdal.com<<
snip
Cheers, Tuck |
